Information Provided By: 
Fly News Breaks for November 30, 2018
AMRN
Nov 30, 2018 | 07:26 EDT
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on Amarin with a $35 price target. The analyst continues to think that the peak sales opportunity for Vascepa, post positive Reduce-It results, is still underappreciated. Prescriptions for Vascepa continue to accelerate post the positive results and Q4 has historically been Amarin's best quarter of the year, Chen tells investors in a research note titled "Buckle Up, Because Vascepa Rxs Could Take Off Soon."
News For AMRN From the Last 2 Days
There are no results for your query AMRN
